FDA Hits Empower Pharmacy With Third GLP-1 Warning

The FDA issued a warning letter to Houston-based Empower Pharmacy over its compounded GLP-1 weight loss treatments, the third warning the compounder has received in less than two years.

The Food and Drug Administration has sent a warning letter to Empower Pharmacy over the Houston company's compounded GLP-1 weight loss treatments. It is the third warning Empower has received from the agency in less than two years, according to Endpoints News.

A warning letter is the FDA's formal notice that it has found violations serious enough to require prompt correction. It is not a fine and not a shutdown order, but it is the step the agency typically takes before it escalates to injunctions, seizures or consent decrees. Receiving one is unwelcome. Receiving a third inside two years is the kind of pattern that regulators cite when they argue a firm's corrective actions have not stuck.

Why a compounder is in the GLP-1 business at all

Compounding pharmacies exist to make drugs that patients cannot get off the shelf — a different dose, a liquid instead of a tablet, a formulation without an allergen. Under federal law, they can also make copies of commercial drugs when those drugs are in short supply. That exception is what opened the door to the compounded GLP-1 trade: when demand for semaglutide and tirzepatide-based weight loss injections outran supply, compounders stepped in at a fraction of branded list prices, often distributed through telehealth platforms that bundled the prescription, the shipment and the follow-up into a monthly subscription.

The economics were compelling for patients paying cash, and the volume grew fast. But compounded products do not go through the FDA's premarket review. Nobody has inspected the specific formulation, the sterility assurance or the potency of each batch the way they would for an approved injectable. That is the regulatory gap the agency has been working to close, and the reason inspections of high-volume GLP-1 compounders have become a standing feature of the FDA's enforcement calendar.

Third strike changes the calculus

The significance of this letter is less about any single observation than about repetition. Regulators treat repeat findings differently from first findings. A first letter invites a response and a remediation plan. A second suggests the plan was inadequate. A third puts the question of whether the company's quality systems can be relied upon at the centre of the file — and gives the agency a documented history to point to if it decides the next step should be a court-enforced remedy rather than another letter.

For Empower, the practical exposure runs along several lines at once:

• Product scope. If the FDA presses on specific GLP-1 preparations, the company may have to stop or reformulate them, which hits the fastest-growing part of the compounded market.
• Channel risk. Telehealth partners and prescribers weigh liability. A documented enforcement history is the sort of thing that makes a platform's compliance team look for another supplier.
• State boards. Pharmacy licensure sits with states, and state boards routinely take federal findings as their own starting point.
• Payer and employer channels. Any move toward reimbursed or employer-sponsored weight loss programs requires a clean regulatory record.

What it means for Novo Nordisk and Eli Lilly

The branded makers of GLP-1 obesity drugs have argued consistently that mass-scale compounded copies are neither authorized nor adequately controlled, and they have pursued that argument through litigation and through complaints to regulators. Every enforcement action against a large compounder narrows the grey market that has been absorbing cash-pay demand at prices the brands do not match.

That does not translate mechanically into branded volume. A patient paying out of pocket for a compounded vial may not simply switch to a list-price branded pen; some will drop off treatment, and others will move to the lower-priced direct-to-consumer offers the manufacturers themselves have built. But the direction of travel is clear enough: the compounded channel is being squeezed from two sides, by regulatory pressure on the compounders and by price competition from the brands.

Novo Nordisk's shares have been volatile through this period — the stock fell 8% in a recent session on a sell-side call, a reminder that obesity-drug sentiment is being repriced on news flow rather than on any single enforcement action. The market did not treat Monday's session as a sector event: the S&P 500 (SPY) closed at $773.38, down 0.02% on the day, while the Nasdaq 100 (QQQ) finished at $747.46, up 0.81%, and the Dow 30 (DIA) closed at $518.00, down 0.34%, as of the last trade at 20:00 GMT on 22 September 2026. Empower is privately held, so there is no listed equity to register the news directly.

The enforcement pattern worth tracking

What to watch from here is whether the agency publishes the specific observations behind the letter, how quickly Empower responds on the record, and whether the FDA follows with an import alert, a recall request or referral for judicial action. Warning letters carry a response deadline; the content and credibility of that response usually determines whether the file closes or escalates.

The broader question is structural. The compounded GLP-1 market grew up inside a shortage exception that was never designed to support a national weight loss industry. As supply of the branded products normalized and the shortage justification weakened, the legal footing under large-scale compounding of these molecules thinned. Enforcement letters are the visible edge of that shift. Clinics, telehealth companies and the patients who rely on cheaper injections are the ones who feel it, and they tend to feel it abruptly — a supplier stops shipping, and a monthly refill becomes a phone call to a prescriber asking what is left.

For investors, the read-through is not that any one compounder matters to the earnings of any one pharmaceutical company. It is that the cash-pay obesity market is being reorganized in public, one regulatory document at a time, and that the share of demand currently served outside the approved-drug system is likely to keep shrinking.

Key facts

• Regulatory action: FDA warning letter to Empower Pharmacy over compounded GLP-1 weight loss treatments
• Enforcement history: Third FDA warning to the company in less than two years
• Company base: Houston, Texas; privately held, no listed ticker
• Market backdrop: S&P 500 (SPY) last close $773.38, -0.02%, as of 20:00 GMT, 22 Sep 2026

Frequently asked questions

What is an FDA warning letter?

A warning letter is the FDA's formal written notice that it has identified violations of federal law serious enough to require prompt correction. It is not a fine or a closure order, but it establishes a documented record. If a company fails to respond adequately, the agency can escalate to injunctions, product seizures, import alerts or referral for judicial action.

Why was Empower Pharmacy cited?

The FDA issued the warning letter in connection with Empower's compounded GLP-1 weight loss treatments. Empower, based in Houston, has now received three FDA warnings in less than two years. The agency has been inspecting high-volume compounders of GLP-1 products as the cash-pay weight loss market expanded outside the approved-drug system.

How can compounders make copies of GLP-1 drugs?

Federal law allows compounding pharmacies to prepare versions of commercial drugs when those drugs are in short supply, alongside their core role of making customized formulations. That shortage exception is what enabled large-scale compounded semaglutide and tirzepatide products. Compounded drugs do not undergo FDA premarket review for safety, potency or manufacturing quality.

Does this affect Novo Nordisk and Eli Lilly?

Indirectly. Both branded manufacturers have argued that mass-scale compounded copies are unauthorized and inadequately controlled. Enforcement against large compounders narrows the grey-market channel serving cash-pay patients. It does not guarantee those patients switch to branded pens — some stop treatment, others move to lower-priced direct-to-consumer offerings from the manufacturers.

Can I still buy compounded GLP-1 injections?

Availability depends on the individual pharmacy and on state and federal action. A warning letter does not by itself stop shipments, but it can prompt a company to halt or reformulate specific products, and telehealth partners may switch suppliers. Patients relying on compounded refills should ask their prescriber about alternatives in advance.

Is Empower Pharmacy publicly traded?

No. Empower Pharmacy is a privately held company based in Houston, so there is no exchange-listed stock that reflects the FDA action directly. Investors tracking the compounded weight loss market generally read these enforcement events through the listed branded manufacturers and through telehealth platforms that distribute compounded products.

Sources

• Compounder Empower receives FDA warning letter over GLP-1s — Endpoints News